Amgen at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Amgen at ASHG 2026 in Montréal: 2 presentations (1 poster, 1 plenary).

Organization	ASHG 2026 Attendance
Amgen Greater Boston, Massachusetts	1 Principal Scientist · 1 Vice President of Global Research, Head of Cardiometabolic Research, and Head of Human Genetics
amgen.com\|LinkedIn Public company~31,500 people Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. CFO Peter Griffith, in the role since 2020, is retiring; Thomas Dittrich will succeed him. › CFO Peter Griffith, in the role since 2020, is retiring; Thomas Dittrich will succeed him. 2026-05 · source CTO David Reese will retire effective June 30, 2026, as part of broader organizational changes at Amgen. 2026-04 · source Acquired Dark Blue Therapeutics to strengthen its oncology pipeline, adding new drug-development programs. 2026-01 · source Source: company newsroom Q2 2026 revenue $10.1B, up 10%; FY26 guidance $38.2-39.4B › Steady double-digit growth with two C-suite retirements underway, a leadership transition to watch. · 2026-08-04 “For the second quarter, total revenues increased 10% to $10.1 billion in comparison to the second quarter of 2025. For the full year 2026, the Company expects: Total revenues in the range of $38.2 billion to $39.4 billion.” Source: results release Currently hiring: 1,591 open roles › Source: careers page	Poster Thu Oct 22 4:15 pm Part of Complex Traits and Polygenic Disorders Poster Thursday Session Temporal Transcriptomic Profiling Identifies Core Regulators in Cytokine-Induced Gut Barrier Disruption in Differentiated Caco-2 Cells Exhibit & Poster Hall · Board 8318T TranscriptomeCharacterization of disordersGastrointestinal systemRNA-seq Plenary Sat Oct 24 11:50 am Part of Globalizing Human Genetics: From Discovery Through Implementation Genetics across communities advance heart attack prevention globally Room 517/Level 5 1 invited symposium speaker

Organization

ASHG 2026 Attendance

Greater Boston, Massachusetts

1 Principal Scientist · 1 Vice President of Global Research, Head of Cardiometabolic Research, and Head of Human Genetics

amgen.com|LinkedIn

Public company~31,500 people

Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases.

CFO Peter Griffith, in the role since 2020, is retiring; Thomas Dittrich will succeed him.

›

CFO Peter Griffith, in the role since 2020, is retiring; Thomas Dittrich will succeed him.

2026-05 · source

CTO David Reese will retire effective June 30, 2026, as part of broader organizational changes at Amgen.

2026-04 · source

Acquired Dark Blue Therapeutics to strengthen its oncology pipeline, adding new drug-development programs.

2026-01 · source

Source: company newsroom

Q2 2026 revenue $10.1B, up 10%; FY26 guidance $38.2-39.4B

›

Steady double-digit growth with two C-suite retirements underway, a leadership transition to watch. · 2026-08-04

“For the second quarter, total revenues increased 10% to $10.1 billion in comparison to the second quarter of 2025. For the full year 2026, the Company expects: Total revenues in the range of $38.2 billion to $39.4 billion.”

Source: results release

Currently hiring: 1,591 open roles

›

Source: careers page

Poster

Thu Oct 22
4:15 pm

Part of Complex Traits and Polygenic Disorders Poster Thursday Session

Temporal Transcriptomic Profiling Identifies Core Regulators in Cytokine-Induced Gut Barrier Disruption in Differentiated Caco-2 Cells

Exhibit & Poster Hall · Board 8318T

TranscriptomeCharacterization of disordersGastrointestinal systemRNA-seq

Plenary

Sat Oct 24
11:50 am